| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1001: Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment |
|
Medicine details |
|
| Medicine name | zanubrutinib (Brukinsa®) |
| Formulation | oral |
| Reference number | 5205 |
| Indication | Treatment for relapsed or refractory marginal zone B-cell lymphoma |
| Company | BeiGene |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 04/09/2024 |
| NICE guidance | TA1001: Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment |